MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.
Bo
Michele Dal
MD
Secchiero
Paola
P
Degan
Massimo
M
Marconi
Daniela
D
Bomben
Riccardo
R
Pozzato
Gabriele
G
Gaidano
Gianluca
G
Del Poeta
Giovanni
G
Forconi
Francesco
F
Zauli
Giorgio
G
Gattei
Valter
V
D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018797:Cell Cycle Proteins; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism*; D009687:Nuclear Proteins / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D007093:Imidazoles; C482775:MDM4 protein, human; D009687:Nuclear Proteins; D010879:Piperazines; D011518:Proto-Oncogene Proteins; C482205:nutlin 3